Knowledge, Attitudes and Practices of Safe Handling of CDs
NCT06857656 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2025-03-04
Summary
Cancer is a leading contributor to global disease burden, with nearly 20 million new cases diagnosed every year . Cancer patients usually receive a combination of treatments involving surgery, radiation, and/or systemic drug therapy.
Antineoplastic drugs (ADs), also known as chemotherapy or cytotoxic drugs, include compounds with various mechanisms of action that are used to fight the global burden of cancer, preventing or disrupting cell division of neoplastic cells. Also, Antineoplastic drugs are being used increasingly to treat arthritis, multiple sclerosis, and other non-cancer medical conditions.
However, their action on malignant cells is only partially selective and normal cells may also be affected, leading to significant toxic side effects.
Healthcare workers, particularly those working in oncology units, face the possibility of exposure to hazardous antineoplastic drugs, which are known to cause long-term health effects such as cancer, reproductive toxicity, and other chronic health issues. However, there is a gap in research specifically focused on exposure levels and health risks for nurses and pharmacists in tertiary care hospitals. Understanding the impact of this exposure and implementing proper preventive measures is crucial for ensuring the safety of healthcare workers.
The aim of the study:
General objectives: Evaluate the extent of exposure to a The widespread use of CDs has raised concern about the risks health care workers who use them.
Anyone working with patients (or animals) receiving cytotoxic drugs is at risk of exposure. This includes pharmacists, pharmacy technicians, medical and nursing staff, laboratory staff and Veterinary practitioners in which they are all at risk when using cytotoxics. Appropriate control measures must be in place to protect them all Occupational exposure to cytotoxic drugs (CDs) and related wastes may occur during preparing, administering, transporting, storing drugs and when handling cytotoxic waste, transporting and disposing of waste, and cleaning up spills. Exposure to those drugs may occur through skin absorption, inhalation of aerosols and drug droplets, eye contact through a splash of liquids, ingestion, and through needle stick injuries.
In Egypt, the burden of cancer is high; there is low number of nurses especially oncology certified nurses in compared to the patient's number. This makes nurses overwhelmed and frustrated, so, more exposed to CDs hazards.
Acute health effects related to this occupational exposure include hair loss, skin rash, eczema, skin flush, light headedness, nausea, dizziness, vomiting and gastrointestinal symptoms. While the long-term exposure may cause adverse reproductive outcomes including menstrual irregularities, infertility, spontaneous abortion and congenital malformation.
We need to mention results of previous studies Health care workers who handle CDs must be aware of the existing hazards and safe handling practices of cytotoxic drugs because this has been associated with improvement of safety of both patients and health care workers. Previous Egyptian studies show weak compliance of nurses' practice with safe-handling guidelines.
Safe handling of antineoplastic agents is a primary concern among health care workers (HCWs) due to the harmful effects of CDs. Various organizations like National Institute for Occupational Safety and Health (NIOSH), Occupational Safety and Health Administration (OSHA), American Society of Hospital Pharmacist (ASHP), the Oncology Nursing Society and American Society of Clinical Oncology (ASCO) have recommended safe handling practice guidelines for anti-cancer drugs. These guidelines suggest the application of hierarchy of various strategies of mitigating and controlling workplace hazards. All HCWs must follow these safety guidelines.
Some of the guidelines include modifying the physical structure of the workplace in terms of isolating the drug preparation space, minimizing nurses' contact with the drug, applying standard work methods and utilizing personal protective equipment to achieve the minimum contact of the antineoplastic drugs with the skin or respiratory system of HCWs.
A study was done in Ain Shams University Hospitals in 2019 by El Hosseini DM; Ghanem EA; Gamal DA and demonstrate that almost more than half of the study nurses frequently complained from recurrent headache (64.4%), skin irritation (63%), eye irritation (61.6%), and hair loss (52.1%). Reproductive effects were also found: menstrual irregularities (32.9%), low birth weight babies (23.3%), premature labor (19.2%), and malignancy (15.1%). During handling CDs, the majority of nurses (89%) utilized gloves, (61.6%) utilized gowns, and none of them utilized goggles. About (72. %) had fair total knowledge score regarding CDs, and only few of them (11.0 %) had good total In the last four decades, several studies have reported detectable and/or quantifiable concentrations of such hazardous drugs both in wor
Conditions
- Cytotoxic Drug
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-04-01
- Primary Completion
- 2026-04-01
- Completion
- 2026-05-01
More Related Trials
-
Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle
NCT00703378 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852 ·Status: RECRUITING ·Phase: PHASE3
-
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
NCT07167446 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Dexanabinol in Patients With Brain Cancer
NCT01654497 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy
NCT04327583 ·Status: UNKNOWN ·Phase: NA
-
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
NCT00382733 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Evaluating Occupational Exposure to Antineoplastic Drugs
NCT06343103 ·Status: RECRUITING ·Phase: NA
-
Optimizing the Management of Patients With Oral Therapy
NCT03623490 ·Status: TERMINATED ·Phase: NA
-
Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy
NCT07241182 ·Status: RECRUITING ·Phase: NA
-
Antineoplastic Drugs in Elderly Patients
NCT05467189 ·Status: RECRUITING
-
Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer
NCT06469957 ·Status: COMPLETED
-
Tolerance of Anti-Cancer Therapy in the Elderly
NCT05251922 ·Status: UNKNOWN
-
Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer
NCT03535701 ·Status: COMPLETED ·Phase: PHASE1
-
A Survey of Parent/Caregiver Practices on the Storage, Use, and Disposal of Opioids in a Comprehensive Cancer Center
NCT03390283 ·Status: COMPLETED
-
Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients
NCT06297369 ·Status: RECRUITING ·Phase: PHASE2
-
Livertoxcicity in Acute Leukemia Patients During Chemotherapy Treatment
NCT06383325 ·Status: NOT_YET_RECRUITING
-
Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy
NCT04582591 ·Status: UNKNOWN ·Phase: PHASE2
-
Tc-99m Renography and Cisplatin-induced Nephrotoxicity
NCT00213642 ·Status: TERMINATED
-
Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer
NCT06367335 ·Status: COMPLETED
-
Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines
NCT00838370 ·Status: COMPLETED ·Phase: PHASE1
-
The Effects of Clostridium Butyricum on Adverse Events During Adjuvant Chemotherapy for Colorectal Cancer
NCT07152886 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring
NCT01053104 ·Status: COMPLETED
-
Diet, Hepcidin, and Chemotherapy RDI
NCT06483997 ·Status: ACTIVE_NOT_RECRUITING
-
Impact of Clinical Pharmacy Consultations in Patients With Cancer Treated With Oral Anti-cancer Therapies on the Rate of Serious Adverse Events
NCT02733965 ·Status: UNKNOWN ·Phase: NA
-
Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients with Risk Factors
NCT03257969 ·Status: RECRUITING ·Phase: NA